PFBT
AKBA icon

Parkside Financial Bank & Trust’s Akebia Therapeutics AKBA Stock Holding History

Parkside Financial Bank & Trust’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-426
Closed -$1.16K – 2685
2025
Q3 		$1.16K Buy
426
+181
+74% +$602 ﹤0.01% 2222
2025
Q2 		$890 Buy
+245
New +$673 ﹤0.01% 2312

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Parkside Financial Bank & Trust's AKBA Position: Q4 2025 in Review

Parkside Financial Bank & Trust sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 426 shares — an estimated $1.16K sold.

Parkside Financial Bank & Trust first reported a position in AKBA in Q2 2025 and held it in 2 quarters. The position peaked at $1.16K in Q3 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

  • Parkside Financial Bank & Trust reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 426 Akebia Therapeutics shares in Q4 2025, an estimated $1.16K.
  • Parkside Financial Bank & Trust first reported a position in Akebia Therapeutics in Q2 2025 and held it in 2 quarters.
  • Parkside Financial Bank & Trust's Akebia Therapeutics position peaked at $1.16K in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Parkside Financial Bank & Trust's 13F filing for Q4 2025, filed 13 Feb 2026.